Table 1.
Neutralizing Antibody Therapy
| Clinical Trial Identifier | Phase | Intervention | Status |
|---|---|---|---|
| NCT04429529 | Phase 1 | Biological: TY027 | Completed |
| NCT04931238 | Phase 1 | Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody) | Recruiting |
| NCT04840459 | Phase 2 | Biological: bamlanivimab, casirivimab, imdevimab | Recruiting |
| NCT04787211 | Phase 2 | BRII-196 and BRII-198 | Recruiting |
| NCT04425629 | Phase 2/Phase 3 | REGN10933+REGN10987 combination therapy | Recruiting |
| NCT04426695 | Phase1/Phase 2 | REGN10933+REGN10987 combination therapy | Completed |
| NCT04409509 | Phase 2 | Garadacimab, Factor XIIa Antagonist Monoclonal Antibody | Completed |
| NCT04441918 | Phase 1 | Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody) | Recruiting |
| NCT04644185 | Phase 2/Phase 3 | SCTA01 | Recruiting |
| NCT04464395 | Phase 1 | CPI-006 | Completed |
| NCT04913675 | Phase 3 | VIR-7831 | Recruiting |
| NCT04516564 | Phase 1 | AK119 | Recruiting |